Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 8/20 | 0.51 |
| ▸ | MAOA | P21397 | 8/20 | 0.47 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1176965 | 0.77 | MAOA (0.67) | PYCR1MAOAMAOBLMNAUSP2 | |
| SCHEMBL3064865 | 0.75 | TAAR1 (0.61) | TAAR1 | |
| Hydrochloric Acid SCHEMBL28077090 | 0.75 | LMNA (0.68) | PYCR1MAOAMAOBLMNAUSP2 | |
| SCHEMBL14426285 | 0.74 | CARM1 (0.55) | PYCR1MAOAMAOBLMNAUSP2 | |
| SCHEMBL237082 | 0.74 | TAAR1 (0.54) | PYCR1LMNATSHRALDH1A1TAAR1 | |
| Hydrochloric Acid SCHEMBL28135517 | 0.74 | TAAR1 (0.59) | SMN1; SMN2TAAR1 | |
| SCHEMBL7283026 | 0.70 | SIGMAR1 (0.62) | PYCR1MAOAMAOBLMNAUSP2 | |
| SCHEMBL143962 | 0.70 | TAAR1 (0.71) | LMNATSHRALDH1A1SMN1; SMN2TAAR1 | |
| SCHEMBL3645165 | 0.69 | TAAR1 (0.46) | PYCR1LMNATSHRALDH1A1TAAR1 | |
| SCHEMBL30097626 | 0.69 | TAAR1 (0.46) | PYCR1LMNATSHRALDH1A1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0833623-A1 | METHOD FOR TREATING MULTIPLE SCLEROSIS | Harris, Richard Y. (US) | 1998-04-08 | — | — | EP | claimed |
| US-5679715-A | Method for treating multiple sclerosis | HARRIS RICHARD Y (US) | 1997-10-21 | — | — | US | claimed |
| WO-1996040095-A1 | METHOD FOR TREATING MULTIPLE SCLEROSIS | HARRIS RICHARD Y (US) | 1996-12-19 | — | — | WO | claimed |
| US-9370499-B2 | Androgen receptor-dependent gene expression control | UNIVERSITAETSKLINIKUM FREIBURG (DE) | 2016-06-21 | — | — | US | disclosed |
| US-20140206770-A1 | ANDROGEN RECEPTOR-DEPENDENT GENE EXPRESSION CONTROL | UNIVERSITAETSKLINIKUM FREIBURG (DE) | 2014-07-24 | — | — | US | disclosed |
| US-8680157-B2 | Androgen receptor-dependent gene expression control | UNIVERSITAETSKLINIKUM FREIBURG (DE) | 2014-03-25 | — | — | US | disclosed |
| EP-1693383-B1 | Antibodies for use in identifying prostate cancer | UNIVERSITAETSKLINIKUM FREIBURG (DE) | 2013-10-09 | — | — | EP | disclosed |
| US-7858395-B2 | Antibodies for use in identifying and/or scoring prostate cancer and androgen receptor-dependent gene expression control | UNIVERSITAETSKLINIKUM FREIBURG (DE) | 2010-12-28 | — | — | US | disclosed |
| EP-1704859-B1 | Androgen receptor-dependent gene expression control by inhibiting the amine oxidase activity of lysine-specific demethylase (LSD1) | UNIVERSITAETSKLINIKUM FREIBURG (DE) | 2010-08-11 | — | — | EP | disclosed |
| US-20100189819-A1 | NEURO-DEGENERATIVE INHIBITOR, NEURO-ENDOCRINE MODULATOR, AND NEURO-CEREBRAL METABOLISM ENHANCER | INTRATHERAPIES LLC (US) | 2010-07-29 | — | — | US | disclosed |
| US-20090104196-A1 | Antibodies For Use in Identifying and/or Scoring Prostate Cancer and Androgen Receptor-Dependent Gene Expression Control | UNIVERSITAETSKLINIKUM FREIBURG (DE) | 2009-04-23 | — | — | US | disclosed |
| US-20030012740-A1 | Delivery of compounds for the treatment of parkinsons through an inhalation route | ALEXZA PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | disclosed |
| WO-2002094235-A1 | DELIVERY OF COMPOUNDS FOR THE TREATMENT OF PARKINSONS THROUGH AN INHALATION ROUTE | ALEXZA MOLECULAR DELIVERY CORPORATION (US) | 2002-11-28 | — | — | WO | disclosed |
| US-20020168403-A1 | Compositions and therapy for substance addiction | BIBERMAN RONI (IL) | 2002-11-14 | — | — | US | disclosed |
| US-20020019421-A1 | Compositions and therapy for substance addiction | BIBERMAN RONI (IL) | 2002-02-14 | — | — | US | disclosed |
| US-6313176-B1 | SELECTING AN IRREVERSIBLE ENZYME INHIBITOR AS A MEDICAMENT THAT IS METABOLIZED INTO AN UNWANTED OR ADVERSIVE METABOLITE; PLACING IRREVERSIBLE ENZYME INHIBITOR IN A SUITABLE FORMULATION; ADMINISTERING FORMULATION FOR THERAPY | ELLINWOOD JR EVERETT J (US) | 2001-11-06 | — | — | US | disclosed |
| EP-0833623-A1 | METHOD FOR TREATING MULTIPLE SCLEROSIS | Harris, Richard Y. (US) | 1998-04-08 | — | — | EP | disclosed |
| US-5679715-A | Method for treating multiple sclerosis | HARRIS RICHARD Y (US) | 1997-10-21 | — | — | US | disclosed |
| US-5679715-A | Method for treating multiple sclerosis | HARRIS RICHARD Y (US) | 1997-10-21 | — | — | US | disclosed |
| WO-1996040095-A1 | METHOD FOR TREATING MULTIPLE SCLEROSIS | HARRIS RICHARD Y (US) | 1996-12-19 | — | — | WO | disclosed |